Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Methyl Salicylate→

Methyl Salicylate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
119-36-8
Molecular formula
C8H8O3
Molecular weight
152.1473 g/mol
Drug class
Topical counterirritantsalicylate ester used in external analgesic products
Mechanism of action
Applied topically, methyl salicylate produces local counterirritant and warming effects. It is absorbed through skin and hydrolysed to salicylate, which can inhibit cyclo-oxygenase and prostaglandin synthesis; systemic exposure can occur with excessive application or occlusion.
Indications / reported uses
  • Temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains in authorised topical external-analgesic formulations

Sources: US eCFR — External analgesic drug products, 21 CFR Part 348 · NLM MeSH — Methyl salicylate · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical counterirritant; salicylate ester used in external analgesic products

Mechanism of action

Applied topically, methyl salicylate produces local counterirritant and warming effects. It is absorbed through skin and hydrolysed to salicylate, which can inhibit cyclo-oxygenase and prostaglandin synthesis; systemic exposure can occur with excessive application or occlusion.

General use cases

  • Temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains in authorised topical external-analgesic formulations

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Methyl Salicylate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Methyl Salicylate Permitted Daily Exposure (PDE) report (the Methyl Salicylate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Methyl Salicylate Occupational Exposure Limit (OEL) report (the Methyl Salicylate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.